top of page
News, Events and Updates
Search
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Jan 8
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Dec 18, 2025
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Dec 12, 2025
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
Nov 18, 2025
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Sep 2, 2025
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Aug 12, 2025
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Aug 5, 2025
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
May 13, 2025
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
May 6, 2025
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
Apr 23, 2025
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Feb 12, 2025
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
Feb 5, 2025
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Jan 15, 2025
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Jan 13, 2025
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 6, 2025
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Dec 23, 2024
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Dec 16, 2024
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 31, 2024
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 6, 2024
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Aug 1, 2024
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
